BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2017
Price : $35 *
At a glance
- Drugs Nesiritide (Primary)
- Indications Cardiovascular disorders; Diabetes mellitus; Obesity
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 10 Oct 2017 Status changed from active, no longer recruiting to completed.
- 27 Oct 2015 Planned End Date changed from 1 Dec 2015 Jun 2008 to 1 Jun 2018 as reported by ClinicalTrials.gov.